GILD vs. TEM: Gilead Sciences vs. Tempus AI Stock Comparison

Company Profile

Gilead Sciences (GILD) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Gilead Sciences (GILD) carries decades of public-market history since January 22, 1992, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the GILD side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Gilead Sciences (GILD) is defensive at 0.36 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Gilead Sciences (GILD) at -22.45% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Both Gilead Sciences (GILD) at -12.46% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Gilead Sciences (GILD) reports 42.43%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Gilead Sciences (GILD) at 2.39% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

Debt sits unusually high against shareholders’ equity for both Gilead Sciences (GILD) at 2.02 and Tempus AI (TEM) at 2.86 — each debt-to-equity ratio is above its industry benchmark range.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Neither Gilead Sciences (GILD) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both Gilead Sciences (GILD) at 15.88 and Tempus AI (TEM) at 27.66 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics